Press Releases
Press Releases
-
May 19, 2022
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report -
May 17, 2022
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting -
May 16, 2022
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV -
May 2, 2022
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation -
April 28, 2022
Gilead Sciences Announces First Quarter 2022 Financial Results -
April 26, 2022
Gilead Sciences to Present at Upcoming Investor Conferences -
April 25, 2022
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19 -
April 24, 2022
Several New Studies Presented at ECCMID 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19 -
April 19, 2022
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland -
April 14, 2022
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022